Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saquinavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saquinavir SCHEMBL29534530 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL13953012 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL6881 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL1976548 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL13575784 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL8584252 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL1176566 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL8584255 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL21683360 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL29357501 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041764-A1 | Sustained-Release Oral Fosamprenavir Formulation for Treatment of Reflux | N-ZYME BIOMEDICAL INC. (CA) | 2024-02-08 | — | — | US | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230172846-A1 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2023-06-08 | — | — | US | disclosed |
| EP-3482762-A1 | A SOLID PHARMACEUTICAL DOSAGE FORMULATION COMPRISING LOPINAVIR | AbbVie Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20180221406-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | FORESIGHT BIOTHERAPEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| CN-102260243-B | Saquinavir succinic acid half ester salt and its preparation | SHENYANG ELIVING MEDICAL TECHNOLOGY CO LTD | 2013-08-14 | — | — | CN | disclosed |
| CN-102260243-A | Saquinavir succinic acid half ester salt and its preparation | — | 2011-11-30 | — | — | CN | disclosed |
| CN-1282736-A | Method of preparing medicinal active substance derived from quinogold | HOFFMANN LA ROCHE (CH) | 2001-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221406-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | EIF2AK2, IRF3, IFNG | CYP3A4 825/4885ABCC4 3367/4885ABCB11 3192/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | CYP3A4 3014/4885ABCC4 3734/4885ABCB11 2499/4885 |
| US-20230172846-A1 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | DSTN, FDFT1, DDHD2 | CYP3A4 328/4885ABCC4 3385/4885ABCB11 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.